National and Kapodistrian University of Athens
Προγνωστική αξία της αντιπονεκτίνης και της ιντερλευκίνης -10 (IL-10) στην οξεία παγκρεατίτιδα
Abstract
dc:descriptionIntroduction: Acute pancreatitis usually follows a mild self-limiting course with complete recovery. However, approximately 20% -30% of patients present with a severe clinical picture, which is associated with the morphological association of intrapancreatic and extrapancreatic necrosis. Depending on the presence and extent of necrosis, pancreatic infections were observed in 30% - 70% of patients and are associated with a significant increase in morbidity and mortality.Early and accurate diagnosis of pancreatic infection is of major importance because it strongly influences further treatment decisions. Most patients with sterile necrosis are successfully managed with conservative treatment, and proven pancreatic infection with generalized sepsis is an indication for invasive or surgical treatment.Faced with this dilemma, there is great interest in a valid means of diagnosing pancreatic infection and sepsis. In addition to the various multifactorial scoring systems, a number of biochemical variables have been studied in acute pancreatitis and have been shown to be valid criteria for predicting disease severity. However, it is already documented that they have little value in distinguishing pancreatic infection and related sepsis from non-infectious systemic inflammatory response syndrome (SIRS). Purpose: An accurate determination of biochemical parameters to identify patients at risk of developing pancreatic infections will certainly contribute to an easier and safer diagnosis. So we have gathered the most promising indicators that can be used as population control indicators for acute pancreatitis according to the most recent publications in international journals and the literature, but which have not yet been sufficiently studied.These markers were measured in both patients with acute pancreatitis and patients with pancreatic cancer, as these two diseases of the pancreas share many common signaling pathways, common physiopathological mechanisms and are the two most important diseases of the pancreas that concern them, nowadays and for which early prognosis is of great importance with important medical and social implications.The indicators studied for both patients with acute pancreatitis and patients with pancreatic cancer as well as healthy controls are: Adiponectin. Interleukin 10, Osteonectin, Neurotensin and Tumor Growth Factor (TGF).Material and methods: All samples were taken on the day of patient admission. After centrifugation at 3000 rpm for 10 minutes, the serum was separated from the red ones and stored at -80 ° C until the agents under study were determined.General exclusion criteria are:•interval between the onset of abdominal symptoms and inclusion in the study> 96 hours, •absence of SIRS,•age under 18 years,•hepatitis B, C, or HIV,•psychoses except of scary delirium and•Previous surgeries or any type of surgery on the pancreas.General inclusion criteria for acute pancreatitis are:•Time interval between the onset of typical abdominal symptoms and inclusion in the study is 96 hours or less,•Presence of SIRS•Updated consent.Specific inclusion criteria for severe acute pancreatitis are: •At least 3-fold increased amylase or lipase levels•The presence of intra-pancreatic / extra-pancreatic necrosis documented by CT or CRP> 250 mg / L••Or alternatively, at least one non-functional organic system:opulmonary insufficiency: arterial pO2 <60 mmHg in room air or mechanical ventilationoRenal impairment: creatinine> 180 mol/L or hemofiltration/dialysisoShock: systolic blood pressure <80 mmHg for over> 15΄) according to Atlanta criteria.Method for reducing biasUse of healthy volunteers with the same characteristics (gender, age, nationality, habits) and patients suffering from pancreatic cancer. The biometric analyzes were performed by the staff blindly in relation to the patient / healthy material. The null hypothesis H0: p1 = p2 was tested against alternative H1: p1 ≠ p2 using a pair T-test, with p1 and p2 measurements between patients and healthy and patients with pancreatic cancer respectively. We do not have any information on the differences of serum osteonectin between healthy controls, patients and patients with pancreatic cancer. Therefore for the calculation of the patient sample we assumed that we would need the largest possible sample e.g. p1 = 0.45, p2 = 0.55.The calculation of the sampleThe study was designed to document a 10% difference in factor measurements at alpha level = 5% with power 1-beta = 80%. An intermediate analysis was performed after 50% of the patients were enrolled in the study.Initially, the coded data of the study were entered into the computer, followed by a check for the correctness of the data recording. Data analysis was performed using the IBM SPSS 21.0 (Statistical Package for Social Sciences) statistical package for the Windows operating system.To investigate the relationship between a quantitative variable and a bisector variable, the student's t-test was used when the quantitative variable followed the normal distribution, while the Mann-Whitney (Mann-Whitney) control was used when it did not follow the normal distribution. test). The x2 test (chi-square test) and the Fisher exact test (Fisher's exact test) were used to investigate the relationship between two categorical variables.The diagnostic value of the indicators was assessed by sensitivity, specificity, authenticity, the area under the ROC curve and the corresponding 95% confidence interval.The bilateral level of statistical significance was set equal to 0.05. Data analysis was performed with IBM SPSS 21.0 (Statistical Package for Social Sciences).The study population included 41 patients with acute pancreatitis, 13 patients with pancreatic cancer and 24 controls.Results:IL-10 had the best diagnostic capacity in acute pancreatitis having the highest authenticity (86.9%) and the largest area below the ROC curve (89.4%).Interleukin 10 had a diagnostic capacity in pancreatic cancer having an authenticity of 73.8% and an area below the ROC curve of 74.2%.Patients with acute pancreatitis had higher median osteonectin (p <0.001) than the control group.Patients with pancreatic cancer had higher median osteonectin (p <0.001) than the control group.Osteonectin had a diagnostic capacity in acute pancreatitis of 81.2% and an area below the ROC curve of 83.1%.Osteonectin had the best diagnostic capacity in pancreatic cancer having the highest authenticity (86.1%) and the largest area below the ROC curve (85.6%).Conclusions:Serum IL-10 may be a useful tool in the differential diagnosis of both acute pancreatitis and pancreatic cancer.In addition, acute pancreatitis could be the initial clinical manifestation of pancreatic adenocarcinoma and with this in mind the assessment of patients with acute pancreatitis for pancreatic adenocarcinoma could contribute to the early diagnosis of more patients. Especially after the age of 40, when the risk of pancreatic adenocarcinoma increases in patients with acute pancreatitis.In conclusion, serum IL-10 may be a useful tool for the differential diagnosis of both acute pancreatitis and pancreatic cancer in relation to the healthy population.Also serum IL-10 may be a useful tool for the differential diagnosis of acute pancreatitis from pancreatic adenocarcinoma, it is the first study of IL-10 as an indicator of differential diagnosis of acute pancreatitis from pancreatic adenocarcinoma.Prospective studies are needed to validate our findings with a larger sample of patients.This means that serum osteonectin may be a useful tool for the differential diagnosis of both pancreatic cancer and severe acute pancreatitis.Osteonectin values between the two groups differed statistically significantly (p = 0.002).So in conclusion we can say that serum osteonectin may be used as a population control indicator for both pancreatic cancer and acute pancreatitis, but a larger patient sample and prospective study design is needed to validate these results. It is the first study of osteonectin as a population control indicator with recent publications in international journals. It is in line with existing web studies. In the future it may play a role in the detection of PanINs and IPMNs in the precursor phase and be a Prognostic Biochemical factor for stages I / II. But a randomized prospective study with a larger sample of patients is needed.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Karkoylias, Kyriakos
- Καρκούλιας, Κυριάκος
Subjects
dc:subject × 28- Προγνωστική αξία
- Καρκίνος παγκρέατος
- Οξεία παγκρεατίτιδα
- Νεοπλασματικός αυξητικός παράγοντας TGF-b1
- Νευροτενσίνη
- Οστεονεκτίνη
- Αντιπονεκτίνη
- Ιντερλευκίνη-10
- Pancreatic cancer
- Αcute pancreatitis
- Tumor growth factor (TGF-β1)
- Neurotensin
- Osteonectin
- Interleukin-10 (IL-10)
- Antiponectin
- Prognostic value
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Χειρουργική
- Ιατρική Βιοτεχνολογία
- Άλλες Ιατρικές Επιστήμες
- Ιατρική έρευνα και Πειραματική ιατρική
- Clinical Medicine
- Medical and Health Sciences
- Surgery
- Medical Biotechnology
- Other Medical Sciences
- Research and Experimental medicine
Rights
dc:rights- Statement dc:rights
-
- BY_4_0
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/49583